Alcon AG vs BridgeBio Pharma Inc — how do they compare? Alcon AG trades at $72.42 (market cap $36.44B), while BridgeBio Pharma Inc trades at $83.9 (market cap $16.36B). The key difference: Alcon AG is far larger — about 2.2× BridgeBio Pharma Inc's market cap, and Alcon AG pays a 0.48% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| ALC | BBIO | |
|---|---|---|
Market Cap | $36.44B | $16.36B |
Sector | Health | Health |
52-Week High | $90.12 | $90.17 |
52-Week Low | $62.02 | $47.29 |
Enterprise Value | $40.28B | $18.14B |
Dividend Yield | 0.48% | — |
Trailing returns across standard periods
Latest headlines on both assets
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →